The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

23 Nov 2020 08:59

RNS Number : 1549G
GlaxoSmithKline PLC
23 November 2020
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

135,376

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

74,556

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

60,820

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - Ordinary Shares

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

254,091

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

32,278

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

221,813

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - ADS

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

4,692,680

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

64,816

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

4,627,864

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

1,447,405

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

169,776

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,277,629

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRKZMZMRFRGGZG
Date   Source Headline
1st Sep 20237:00 amRNSGSK’s Nucala CRSwNP submission accepted in Japan
31st Aug 20233:16 pmRNSHolding(s) in Company
31st Aug 20233:14 pmRNSHolding(s) in Company
25th Aug 20233:30 pmRNSDirector/PDMR Shareholding
23rd Aug 20233:30 pmRNSDirector/PDMR Shareholding
23rd Aug 20237:00 amRNSShingrix data demonstrate 100% efficacy in China
22nd Aug 20233:30 pmRNSDirector/PDMR Shareholding
10th Aug 20233:30 pmRNSDirector/PDMR Shareholding
9th Aug 20233:30 pmRNSDirector/PDMR Shareholding
8th Aug 20231:05 pmRNSPublication of Base Prospectus
1st Aug 20233:00 pmRNSTotal Voting Rights
31st Jul 20236:00 pmRNSFDA approves new use for Jemperli plus chemo
31st Jul 20233:30 pmRNSDirector/PDMR Shareholding
28th Jul 20233:30 pmRNSDirector/PDMR Shareholding
26th Jul 20237:00 amRNS2nd Quarter Results
24th Jul 20237:00 amRNSCabotegravir LA for PrEP receives positive CHMP
20th Jul 20233:30 pmRNSDirector/PDMR Shareholding
17th Jul 20233:30 pmRNSDirector/PDMR Shareholding
13th Jul 20233:30 pmRNSDirector/PDMR Shareholding
3rd Jul 20233:00 pmRNSTotal Voting Rights
28th Jun 20233:43 pmRNSGSK completes acquisition of BELLUS Health
27th Jun 20237:00 amRNSFDA Fast Track for Gonorrhoea Vaccine Candidate
26th Jun 20237:05 amRNSShingrix approved in Japan for adults 18 and over
26th Jun 20237:00 amRNSGSK daprodustat gains positive EMA CHMP opinion
23rd Jun 20233:37 pmRNSDirector/PDMR Shareholding
23rd Jun 20233:33 pmRNSDirector/PDMR Shareholding
23rd Jun 20233:30 pmRNSDirector/PDMR Shareholding
23rd Jun 20237:00 amRNSStatement: Zantac (ranitidine) litigation
22nd Jun 20237:00 amRNSGSK’s Arexvy recommended by ACIP
21st Jun 20237:00 amRNSSeason two data for GSK Arexvy RSV OA vaccine
16th Jun 20237:00 amRNSExtension of FDA review period for momelotinib
12th Jun 20233:30 pmRNSDirector/PDMR Shareholding
7th Jun 20237:00 amRNSEU authorisation of GSK’s RSV vaccine Arexvy
6th Jun 20237:00 amRNSGSK receives US FDA file acceptance for Jemperli
1st Jun 20233:00 pmRNSTotal Voting Rights
22nd May 20233:30 pmRNSDirector/PDMR Shareholding
16th May 20232:00 pmRNSHolding(s) in Company
15th May 20233:30 pmRNSDirector/PDMR Shareholding
15th May 20233:00 pmRNSBlock listing Interim Review
12th May 20233:30 pmRNSDirector/PDMR Shareholding
12th May 20239:50 amRNSMenABCWY vaccine preliminary phase III results
12th May 20237:05 amRNSStatement: Zantac Litigation Update BC Canada
12th May 20237:00 amRNSGSK completes sale of shares in Haleon plc
11th May 20234:41 pmRNSGSK announces intention to sell shares in Haleon
9th May 20233:30 pmRNSDirector/PDMR Shareholding
4th May 20233:30 pmRNSDirector/PDMR Shareholding
3rd May 20236:20 pmRNSResult of AGM
3rd May 20236:00 pmRNSUS FDA approves GSK’s RSV vaccine for older adults
3rd May 20239:09 amRNSForm 8.3 - Allergy Therapeutics plc
2nd May 20233:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.